Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors

Multiple therapeutic agents have been developed to target the phosphatidylinositol 3-kinase (PI3K) signaling pathway, which is frequently dysregulated in cancer promoting tumor growth and survival. These include pan PI3K inhibitors, which target class Ia PI3K isoforms and have largely shown limited...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Rewcastle, Gordon W, Kolekar, Sharada, Buchanan, Christina M, Gamage, Swarna A, Giddens, Anna C, Tsang, Kit Y, Kendall, Jackie D, Singh, Ripudaman, Lee, Woo-Jeong, Smith, Greg C, Han, Weiping, Matthews, David J, Denny, William A, Shepherd, Peter R, Jamieson, Stephen M.F
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564600/
https://ncbi.nlm.nih.gov/pubmed/28537878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17730
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars